Antifungal resistance monitoring, be aware and be prepared! 

  10 March 2022

The first commercially-available antibiotics, the sulphonamides, were discovered through a trial-and-error approach screening various coal-tar dyes and serendipity played a major role in the discovery of penicillin in the late 1920s. Since then, strategies to discover new antimicrobials have significantly diversified, although there have been few truly novel breakthroughs in recent decades. Research has also led to the development of new anti-viral drugs for the treatment of previously impossible to treat or undiscovered viruses and rapidly emerging diseases such as AIDS and COVID-19, amongst others. Similarly, antifungal agents (also known as antimycotics) have emerged as important tools to combat infection, especially for immunocompromised patients.

This Viewpoint was originally published on the REVIVE website revive.gardp.org, an activity of the Global Antibiotic Research & Development Partnership (GARDP).

Further reading: GARDP
Author(s): Stephen Hawser and Ian Morrissey
Effective Surveillance  
Back

OUR UNDERWRITERS

Unrestricted financial support by:

Antimicrobial Resistance Fighter Coalition

Evotec

JSS University





Technology Database

Display your AMR Technology, Product and Service

Suppliers and Users of Technologies, Products and Services benefit from CAPI.
CAPI (Continuous AMR Partnering Initiative) unites Suppliers and Users worldwide with the aim to add to the curbing of AMR.

Read more and make your own Technology Page >>
What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!